Monkeypox Vaccine, Drug Pipeline Grows Despite Signs Of Slowing Infections

Most Products Remain In Preclinical Development

Since its emergence in the spring, the monkeypox outbreak has spawned a small but growing pipeline of drugs and vaccines, many of them repurposed smallpox products.

The monkeypox outbreak has spawned a small but growing pipeline of vaccines and drugs • Source: Shutterstock

Since it began spreading in the spring and migrated to the US shortly thereafter, monkeypox has yet to explode from an outbreak into a bigger epidemic, let alone a pandemic, and infection rates are already showing signs of plateauing in many areas. Still, the world isn’t out of the woods yet, with large-scale growth of infections still possible. To that end, a small pipeline of drug and vaccine candidates has emerged, many of them repurposed products originally developed for smallpox, despite some hitches in getting programs off the ground.

The US Centers for Disease Control has reported 21,504 cases of monkeypox in the US, while the World Health Organization...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

In Brief: PolyPid’s D-PLEX100 Aces Phase III Trial, US Partner, Submission Eyed

PolyPid's D-PLEX100 meets Phase III endpoints this time around, significantly reducing surgical point infections in abdominal colorectal surgery, and is set for a US approval submission early next year.

Bavarian Nordic Well Placed To Meet Mpox Vaccine Demand

 

The company will ramp up manufacturing of its Jynneos vaccine to meet demand in worst-affected African countries and stockpiling richer nations.  

Cagrisema Leads The Charge For 2025

 

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.